Interview: Australian pharmaceutical group looks forward to exploring new opportunities in Chinese market at 2nd CIIE

Source: Xinhua| 2019-11-01 21:23:33|Editor: ZX
Video PlayerClose

SYDNEY, Nov. 1 (Xinhua) -- One of Australia's leading healthcare companies is looking forward to further exploring the potential of the Chinese market, seeking cooperation opportunities at the 2nd China International Import Expo (CIIE) to bring more high-quality products and services to Chinese consumers, the company CEO told Xinhua in a recent interview.

"As a representative of Australia's healthcare enterprises, Homart group was honored to attend the CIIE for two consecutive years," Lynn Yeh, CEO of Homart Pharmaceutical Group, said.

With global economic growth remaining subdued, Yeh believes the CIIE will inject a lot of positive energy.

"Against the current backdrop, China will have a positive impact on global trade and economic growth by holding the expo."

Established in 1992, Homart is one of Australia's largest cGMP (Current Good Manufacturing Practice) manufacturers of supplementary medicine products. It also produces a range of healthcare, skincare and dairy products covered by 12 brands.

Yeh still remembers the grand occasion when she attended the first CIIE. "Last year, many enterprises were too late to sign up for the expo, so they just lined up outside during the expo in hope of getting in." Yeh said.

"We were lucky to be there, the scale is phenomenal, and there are lots of large enterprises, we also signed several contracts on the spot."

According to Yeh, Homart group's overall sales avenue increased by 65 percent last year, while the sales revenue in the Chinese market increased by about 170 percent.

Benefited enormously from the first CIIE, Homart group made full preparation for this year.

"We become more experienced this year." Yeh said. "We're expanding the booth area, improving the design and bringing our newly developed products."

"We will also send some of our specialists to the Australian national pavilion and actively participate in many matchmaking and contract signing activities."

According to her, China's continuous innovation in opening up the market has also accelerated Homart's pace of development in China.

"China has a large population, and their living standards and consumption level are constantly upgrading, which means their acceptance of high-quality products from all over the world is very high," Yeh said.

"The government has also been creatively and acceptably opening up their policies, so that overseas businesses can better connect with the Chinese market."

She said, currently 70 percent of Homart's products are exported worldwide, and half of them went to the Chinese mainland.

"Our healthcare brand Spring Leaf has opened store on China's Tmall, and other well-known e-commerce platforms."

"The dairy brand Autili is also doing well in China's offline maternal and infant store."

Looking forward to the future, Yeh said the company will invest more in research and development for new products, increase production capacity and seek new opportunities of cooperation in the Chinese market.